Literature DB >> 20713898

Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension.

Elaine Soon1, Alan M Holmes, Carmen M Treacy, Natalie J Doughty, Laura Southgate, Rajiv D Machado, Richard C Trembath, Simon Jennings, Lucy Barker, Paul Nicklin, Christoph Walker, David C Budd, Joanna Pepke-Zaba, Nicholas W Morrell.   

Abstract

BACKGROUND: Inflammation is a feature of pulmonary arterial hypertension (PAH), and increased circulating levels of cytokines are reported in patients with PAH. However, to date, no information exists on the significance of elevated cytokines or their potential as biomarkers. We sought to determine the levels of a range of cytokines in PAH and to examine their impact on survival and relationship to hemodynamic indexes. METHODS AND
RESULTS: We measured levels of serum cytokines (tumor necrosis factor-alpha, interferon-gamma and interleukin-1beta, -2, -4, -5, -6, -8, -10, -12p70, and -13) using ELISAs in idiopathic and heritable PAH patients (n=60). Concurrent clinical data included hemodynamics, 6-minute walk distance, and survival time from sampling to death or transplantation. Healthy volunteers served as control subjects (n=21). PAH patients had significantly higher levels of interleukin-1beta, -2, -4, -6, -8, -10, and -12p70 and tumor necrosis factor-alpha compared with healthy control subjects. Kaplan-Meier analysis showed that levels of interleukin-6, 8, 10, and 12p70 predicted survival in patients. For example, 5-year survival with interleukin-6 levels of >9 pg/mL was 30% compared with 63% for patients with levels < or = 9 pg/mL (P=0.008). In this PAH cohort, cytokine levels were superior to traditional markers of prognosis such as 6-minute walk distance and hemodynamics.
CONCLUSIONS: This study illustrates dysregulation of a broad range of inflammatory mediators in idiopathic and familial PAH and demonstrates that cytokine levels have a previously unrecognized impact on patient survival. They may prove to be useful biomarkers and provide insight into the contribution of inflammation in PAH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713898     DOI: 10.1161/CIRCULATIONAHA.109.933762

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  264 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  Whipple's disease-associated pulmonary hypertension with positive vasodilator response despite severe hemodynamic derangements.

Authors:  Salah Najm; Joud Hajjar; Robert P Nelson; Ramana S Moorthy; Karen M Wolf; Tim Lahm
Journal:  Can Respir J       Date:  2011 Sep-Oct       Impact factor: 2.409

Review 3.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 4.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

5.  Non-suppressive regulatory T cell subset expansion in pulmonary arterial hypertension.

Authors:  Yoshiharu Sada; Yoshihiro Dohi; Sayuri Uga; Akifumi Higashi; Hiroki Kinoshita; Yasuki Kihara
Journal:  Heart Vessels       Date:  2015-08-29       Impact factor: 2.037

Review 6.  MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling.

Authors:  Robert A McDonald; Akiko Hata; Margaret R MacLean; Nicholas W Morrell; Andrew H Baker
Journal:  Cardiovasc Res       Date:  2011-11-07       Impact factor: 10.787

7.  Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension.

Authors:  Jenny Y Chen; Megan Griffiths; Jun Yang; Melanie K Nies; Rachel L Damico; Catherine E Simpson; R Dhananjay Vaidya; Stephanie Brandal; D Dunbar Ivy; Eric D Austin; William C Nichols; Michael W Pauciulo; Katie Lutz; Erika B Rosenzweig; Russel Hirsch; Delphine Yung; Allen D Everett
Journal:  J Pediatr       Date:  2020-08       Impact factor: 4.406

Review 8.  Tumor necrosis factor-α, kidney function, and hypertension.

Authors:  Eamonn Mehaffey; Dewan S A Majid
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 10.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.